Clinical usefulness of telomerase activation and telomere length in head and neck cancer
Clinical usefulness of telomerase activation and telomere length in head and neck cancer
复制标题
DOI：
10.1002/hed.10169
复制
发表时间：
2002-12-01
影响因子：
2.9
通讯作者：
Patel, PS
中科院分区：
文献类型：
--
作者：
Patel, MM;Parekh, LJ;Patel, PS
背景资料。每个复制周期的端粒缩短被认为是限制人类体细胞寿命的原因。相反，端粒酶的激活被认为是癌细胞永生化的关键步骤。与西方国家相比，头颈癌是印度人口中最常见的恶性肿瘤。然而，有关端粒酶活性和端粒长度在头颈癌中的研究报道很少。本文对110例头颈癌和40例癌前病变及良性病变的肿瘤及癌旁正常组织进行了端粒酶活性和端粒长度变化的研究。端粒重复序列扩增法(TRAP)检测端粒酶活性，Southern杂交检测端粒长度。78.2%的癌组织、85%的癌前组织和53.1%的癌旁正常组织有端粒酶活性。在恶性结论中观察到峰值末端限制性片段长度(TRF)显著降低。我们的结果表明，端粒酶活性和端粒长度对头颈癌患者具有重要的临床应用价值。这些标记物可能有助于预测疾病的临床进程，从而识别需要密切随访和积极辅助治疗的患者。(C)2002年威利期刊公司Head Neck 24：10601067,2002。
Background. Telomere shortening at every replication cycle is postulated to limit the life span of human somatic cells. In contrast, activation of telomerase is proposed to be an essential step for cancer cell immortalization. Head and neck cancer is the most common malignancy in the Indian population compared with Western countries. However, there are very few reports on telomerase activity and telomere length in head and neck cancer.Methods. Telomerase activation and telomere length alterations were studied in tumor and adjacent normal tissues in 110 patients with head and neck cancer and 40 patients with precancerous/benign conditions. Telomerase activity and telomere lengths were determined by Telomeric Repeat Amplification Protocol (TRAP assay) and Southern blot analysis, respectively.Results. Telomerase activation was observed in 78.2% of the malignant tissues, 85% of the precancerous tissues, and 53.1% of the adjacent normal tissues. Peak terminal restriction fragment length (TRF) was observed to be significantly lower in malignant Conclusions. Our results demonstrate the significant clinical usefulness of telomerase activation and telomere length for head and neck cancer patients. These markers may be helpful in predicting the clinical course of the disease and thus in identifying the patients in need of a close follow-up and vigorous adjuvant treatment. (C) 2002 Wiley Periodicals, Inc. Head Neck 24: 10601067,2002.